Coronavirus vaccine developer Moderna Inc
MRNA 2.92%
held a virtual R&D event Thursday, showcasing its portfolio and key therapeutic areas.
The Moderna Analysts: Chardan analyst Geulah Livshits has a Buy rating on Moderna with a $95 price target.
SVB Leerink analyst Mani Foroohar maintained an Underpeform rating and $41 price target.
Needham analyst Alan Carr reiterated a Buy rating and $94 price target.
Chardan's 5 Takeaways On Moderna: The news from Moderna's R&D day includes additional visibility on statistical assumptions, monitoring and data analysis for the Phase 3 COVE study of the SARS-CoV-2 vaccine candidate mRNA-1273, Livshits said in a note.
To increase transparency, Moderna has made the trial protocol available online, the analyst said.
The first interim analysis of data from the study — at 53 coronavirus cases — is likely to be released in November, she said, citing the company.